Pharmacy Regulatory updates 06/30/2026

A little late, but better than never ,

Coverage window: Sunday, June 21 – Sunday, June 28, 2026. Delta measured against the June 20 edition; standing frameworks treated as briefed. The Lilly cutoff (executed ~June 18) and the Colorado importation approval (June 15) fell in the prior window and are carried only where they moved this week.

Executive Layer

1. A worsening national shortage of essential generic chemotherapy injectables — ifosfamide among them — is pushing some oncology centers toward explicit rationing, making this the most operationally urgent item this week for your cancer infusion line. Cancer doctors across the U.S. are running short of essential generic chemotherapy drugs, and some fear the squeeze could force widespread rationing; for ifosfamide, used in sarcomas, lymphomas and testicular cancers, some doctors are already meeting to decide who gets treated. Centers for Medicare & Medicaid Services

2. Indiana's Medicaid 340B reimbursement cutoff takes effect July 1 — one day out — with hospitals explicitly not exempt, and I found no FSSA reversal, SPA-approval confirmation, or IHA litigation this week, so DSH entities should assume it loses 340B value on Indiana Medicaid managed-care and FFS claims Wednesday. State officials estimate the change saves Medicaid roughly $63 million annually.

3. The Lilly cutoff fallout continued (nine manufacturers now impose in-house claims-data requirements, AstraZeneca the latest, HHS/HRSA still silent), and the Senate HELP "Perspectives on the 340B Program" hearing platformed witnesses urging the program's outright replacement. A Senate committee witness called for replacing 340B with a direct subsidy program. Instagram

4. Two judicial shifts cut against hospitals this week — the 4th Circuit again sided with drugmakers by vacating the ruling that upheld Maryland's contract-pharmacy law, and the federal government asked the 5th Circuit to overturn the decision upholding Louisiana's law — meaning the Trump DOJ is now actively arguing against state 340B protections.

5. FDA approved two oncology regimens relevant to your infusion book on June 24 — Trodelvy (an antibody-drug conjugate) for first-line triple-negative breast cancer, and a palbociclib-plus-trastuzumab maintenance combination for HR-positive/HER2-positive metastatic breast cancer. FDA approved sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of triple-negative breast cancer, and palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. CMS

6. Section 232 pharma tariffs are unchanged (the June 12 onshoring window closed with no public approvals or MFN signings; next tripwire July 31), while CMS's drug-pricing agenda advanced through the June 12 negotiation proposed rule and June 16 PBM RFI

Section 1 — Federal Regulatory

FDA. A meaningful oncology approval week. On June 24, FDA approved Trodelvy (sacituzumab govitecan) for first-line triple-negative breast cancer as monotherapy and with pembrolizumab, and a palbociclib-plus-trastuzumab (±pertuzumab) maintenance regimen for HR+/HER2+ metastatic breast cancer — both expand your infusion/specialty utilization in breast oncology, and Trodelvy as an ADC carries a tariff wrinkle worth noting (Section 1B). Also in-window, Viridian won approval for Lumvoa in thyroid eye disease (June 26), a specialty/infusion agent that adds a competitor in that niche. On the importation front (new v3 sweep): the FDA Section 804 page shows no new state authorization this period — Colorado's June 15 approval remains the latest, and no pending state (Maine, Vermont, New Hampshire, New Mexico, Texas, North Dakota, Wisconsin) advanced to authorization this week. The dominant FDA story, however, is the chemotherapy shortage, detailed in Section 4.

CMS. No new rule this week. The June 12 Medicare Drug Price Negotiation proposed rule (400+ pages) codifies the program in regulation effective price-applicability year 2029: it codifies the renegotiation process (CMS already selected its first renegotiation drug with the PAY 2028 cohort), changes how combination drugs are treated to stop manufacturers from gaming negotiation eligibility by splitting active ingredients, and implements the statutory small-biotech temporary price floor. The new policies apply to 2029 selections but would reach 2026–2028 drugs if they are renegotiated. The June 16 PBM RFI implements Section 6224 of the CAA 2026 — PBM and affiliate compensation limits plus new PBM data reporting, effective CY2028 — and the two provider-side hooks are the "affiliate" definition (CMS is explicitly asking whether specialty, retail, mail-order, and long-term-care pharmacies, GPOs/rebate aggregators, and wholesalers should count as PBM affiliates) and the pharmacy-payment-arrangement carve-out. Both are worth a comment letter from your seat.

DEA. No change this period. The material item remains the June 9 SUPPORT Act/MAT final rule, effective July 9 (now ~11 days out) — the SOP trigger for your behavioral-health pharmacy's injectable/implantable MOUD workflows. Nothing new in the FR Rules feed or Diversion Control this week.

HRSA. No new agency action this week. The rebate-pilot ICR comment period (published June 15) is running and closes ~July 15; OMB cannot act before then, and the separate criteria/standards Federal Register notice has not posted. HRSA remains publicly silent on Lilly's data policy despite the AHA's renewed demand for enforcement. On the political track, RFK Jr. told a Senate panel he does not know the status of the 340B rebate model and would have HRSA brief the bipartisan "Gang of Six" — a notable admission of how unsettled the rebate posture is at the top of HHS.

Courts. Two adverse moves for hospitals. The 4th Circuit again sided with drugmakers, vacating the ruling that had upheld Maryland's contract-pharmacy access law — a setback in a circuit hospitals had been counting on. And the U.S. government asked the 5th Circuit to overturn the decision upholding Louisiana's contract-pharmacy law; the Trump DOJ siding with manufacturers against a state 340B-protection statute is a meaningful federal-posture signal, because the state-law wave is the main thing currently blunting the manufacturer data cutoffs. For completeness: the Lilly v. HRSA "cash replenishment" suit that I characterized last week as fresh actually traces to Lilly's November 14, 2024 filing (the Kalderos-platform rebate model) and is ongoing rather than new — I'm correcting that. Federal appeals courts also rejected two more drugmaker challenges to Mississippi's law (favorable), and the 1st Circuit (Maine/Rhode Island) and 4th Circuit en banc (West Virginia/Maryland) remain pending. The Senate HELP Committee held its "Perspectives on the 340B Drug Pricing Program" hearing this period; the final transcript is posted, and at least one witness urged replacing 340B with a direct subsidy.

Section 1B — Trade & Tariff Policy (Pharmaceutical)

Quiet — no status change. Short by the delta rule, not trimmed.

Onshoring window / BIS. The June 12 application deadline is now past with no public outcome — applications were confidential submissions to pharma232@bis.doc.gov, and no applicant list, approved agreement, or new Annex addition has been announced. The structure is unchanged: 100% default on patented pharmaceuticals, effective July 31, 2026 for the listed (large) companies and September 29, 2026 for all others; an approved onshoring agreement reduces the rate to 20%, and onshoring plus an MFN agreement to 0% through January 20, 2029. Thirteen companies hold pre-existing Annex II agreements. Next trigger: July 31 — now ~33 days out, the first real invoice event.

ADC carve-out note (ties to this week's FDA approval). Trodelvy, approved June 24, is an antibody-drug conjugate — and ADCs sit in the zero-tariff carve-out alongside orphan drugs, radiopharmaceuticals, plasma-derived therapies, and cell/gene products. So even though it is a patented biologic, it should net out as tariff-exempt regardless of country of origin.

Generics/biosimilars, MFN/CMMI, devices, litigation. No change this period on any. No generic-extension signal (advisory due April 2027); no new MFN signing; the adjacent device/PPE/robotics 232 tracks remain open with no determination; no suit challenging the pharma tariffs.

Section 2 — State Regulatory (Indiana and Ohio)

Indiana. The headline is the calendar: the Medicaid 340B reimbursement cutoff takes effect July 1, hospitals are not covered by the FQHC exemption FSSA granted in May, and I found no finalized FSSA decision reversal, CMS SPA-approval confirmation, or IHA litigation this week — so plan for the cutoff to land Wednesday. The mechanics: Indiana Medicaid stops reimbursing for 340B-purchased drugs and instead pursues manufacturer rebates through the Medicaid Drug Rebate Program, eliminating your ability to generate 340B margin on Indiana Medicaid claims (both managed care and fee-for-service). IHA's Scott Tittle continues to oppose it as a cost shift onto hospitals that jeopardizes access; the Damien Center alone projected a $5 million annual loss. For your DSH entity, model the Medicaid-attributable 340B margin you lose as of July 1 and confirm your split-billing/TPA logic correctly stops claiming 340B on Indiana Medicaid as of that date to avoid duplicate-discount exposure.

Ohio. Nothing material this week. H.B. 229 PBM licensure remains effective July 1, 2027.

National-trend read. The state two-front pattern continued: Minnesota and Connecticut advanced contract-pharmacy access bills, and the litigation around Washington's SB 5981 keeps multiplying (PhRMA and AstraZeneca filed the third and fourth challenges in the prior window). The countervailing signal is the federal government's move against Louisiana's law (Section 1) — if the 5th Circuit agrees the federal government's preemption view, the entire state-protection strategy hospitals are leaning on weakens. On importation (new v3 item): no new Section 804 state authorization this week; Colorado's June 15 approval stands as the trend marker, and hospital pharmacy associations remain opposed.

Section 3 — Payer Policy Updates

Nothing material verified this week across Anthem (IN/OH), UnitedHealthcare, Humana, Aetna, CareSource, or Medical Mutual of Ohio. UHC's oncology cluster from the prior window — June 1 chemo PA via Optum's Cancer Guidance Program, the Aug 1 maintenance/monotherapy site-of-care policy, the Sept 1 injectable-oncology exclusions — remains in execution; no new bulletin-level change surfaced June 21–28. Treat this as "nothing I could confirm in indexed bulletins," not a guarantee — these feeds are portal-gated. Given the chemo shortage (Section 4), watch for payers to issue therapeutic-substitution or non-formulary-exception guidance, which would be the most likely near-term payer move.

Section 4 — Industry Intelligence

Chemotherapy shortage — the operational story of the week. The most actionable item in this brief: essential generic chemotherapy injectables are in serious shortage, with rationing already beginning at some centers. The shortages trace to manufacturing problems, shipping delays, and decisions by some companies to stop making the medicines; these decades-old sterile infusions are hard to produce and command very low prices, yet remain among the most effective options for breast, lung, and head-and-neck cancers when targeted treatments aren't available. Ifosfamide is the named flashpoint, with clinicians convening to make allocation decisions. For your cancer service line this is immediate: stand up (or refresh) a conservation and allocation protocol, confirm your therapeutic-substitution pathways and ethics-committee allocation framework, communicate proactively with your infusion clinicians, and watch for renewed federal supply-chain action (which would tie into the domestic-manufacturing/onshoring theme). This is also a leading edge of the same sterile-injectable economics behind the India NPPA cisplatin/carboplatin price action flagged earlier Centers for Medicare & Medicaid Services

Manufacturer data policies. The count stands at nine manufacturers imposing in-house claims-data requirements, with AstraZeneca the latest to announce and Novo Nordisk having implemented in April; Lilly is the only one to have executed a discount cutoff so far. The running watch: whether a tenth follows, and whether AstraZeneca or others move from announcement to execution. The enforcement model's only brake remains state law — which is why the federal move against Louisiana (Section 1) matters operationally, not just legally.

Drug Channels. No new original post this period. The freshest framing remains the contract-pharmacy concentration data (five firms holding 77% of relationships) and Fein's thesis that the IRA plus CMS's regulatory posture will slow 340B growth and soften covered-entity resistance to a rebate model — reinforced this week by the rebate-ICR timeline and the Senate hearing.

Other. The Premier/GPO first-buy flexibility (HRSA's non-appeal) remains an actionable favorable item from the prior window; and the hospitals' suit against CVS over allegedly siphoning ~$250M in 340B funds (filed May 22) remains live context on the payer-PBM front. No new pharmacy-supply-chain M&A this week. Structurally, the administration's FY27 budget proposal to move 340B from HRSA to CMS remains the sleeper — a 340B program run inside the drug-price-negotiation apparatus would be materially less hospital-friendly.

Section 5 — Closing: Three Things to Watch

1. Regulatory deadlines and court dates in the next 30 days. July 1 — Indiana's Medicaid 340B cutoff for hospitals and the GLP-1 Bridge go-live, same day. July 9 — the DEA SUPPORT Act/MAT final rule takes effect. ~July 15 — the rebate-pilot ICR comment period closes (OMB can't act before then). July 24 — the Section 122 global tariff expires. July 31 — Section 232 large-company tariffs effective, the first real pharmaceutical-tariff invoice event. Decisions pending at the 9th Circuit (Washington), 1st Circuit (Maine/Rhode Island), 4th Circuit en banc (West Virginia/Maryland), and now the 5th Circuit (Louisiana), plus the ongoing Lilly v. HRSA rebate case.

2. Manufacturer or payer moves that may break in the coming week. Whether a tenth manufacturer follows the data-policy trend or AstraZeneca moves to execution; whether HRSA finally responds to the AHA (still silent); HRSA's separate criteria/standards FR notice on the rebate pilot; payer therapeutic-substitution guidance triggered by the chemo shortage; and any onshoring/MFN signing as July 31 approaches.

3. Structurally likely, but not yet news. Two convergences. First, the chemotherapy shortage is likely to renew the push for federal supply-chain intervention — domestic-manufacturing incentives, buffer-stock mandates, or quality-based purchasing — which would intersect directly with the Section 232/onshoring industrial-policy push, an under-appreciated link between your tariff watch and your oncology supply chain. Second, the DOJ's move against Louisiana's law suggests the federal government may broadly adopt a preemption posture against state contract-pharmacy protections; if that view prevails at the 5th Circuit, it would undercut the single mechanism (state law) currently blunting the manufacturer data cutoffs — the most consequential structural risk on the board for a DSH covered entity.